Screener
BioCryst Pharmaceuticals BCRX Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 1,012,140 | 633,311 |
| Stockholders’ deficit: | ||
| Preferred stock, $0.01 par value; shares authorized - 5,000; no shares issued and outstanding at June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.01 par value; shares authorized - 450,000; shares issued and outstanding – 255,265 at June 30, 2026 and 213,060 at December 31, 2025 | 2,553 | 2,131 |
| Additional paid-in capital | 1,693,282 | 1,384,857 |
| Accumulated other comprehensive (loss) income | (528) | 38 |
| Accumulated deficit | (2,149,596) | (1,506,179) |
| Total stockholders’ deficit | (454,289) | (119,153) |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's common stock?
- BioCryst Pharmaceuticals (BCRX) reported common stock of 450M in Q2 2026.
- How has BioCryst Pharmaceuticals's common stock changed year-over-year?
- BioCryst Pharmaceuticals's common stock decreased by 0.0% year-over-year, from 450M to 450M.
- What is the long-term trend for BioCryst Pharmaceuticals's common stock?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's common stock has grown at a 202.8% compound annual growth rate (CAGR), from 1.8M to 450M.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about BioCryst Pharmaceuticals's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude